Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp)
- PMID: 16252067
- DOI: 10.1007/s00702-005-0367-4
Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp)
Abstract
The importance of P-glycoprotein (P-gp) in the pharmacokinetics of amisulpride and the effects of a P-gp inhibitor cyclosporine A (CsA) was investigated both, in vitro and in vivo. In vitro and in vivo results indicated amisulpride as a substrate of P-gp. Amisulpride was not metabolized by rat liver microsomes. Open field behavior showed time dependent abolishment in locomotion by amisulpride (50 mg kg(-1)). Co-administration of CsA (50 mg kg(-1)) resulted in a higher and significantly longer antipsychotic effect (24 h after drug administration). Accordingly, the area under concentration-time curve in serum and brain was higher in CsA co-treated rats (13.5 vs. 29.8 micromol h l(-1) for serum and 2.16 vs 2.98 micromol h l(-1) for brain tissue) while renal clearance was not affected. These results pointed to a pharmacokinetic drug interaction between CsA and amisulpride most likely caused by inhibition of P-gp.
Similar articles
-
Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates.J Pharm Pharmacol. 2004 Aug;56(8):967-75. doi: 10.1211/0022357043969. J Pharm Pharmacol. 2004. PMID: 15285840
-
Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data.J Pharmacol Exp Ther. 2006 May;317(2):704-10. doi: 10.1124/jpet.105.097931. Epub 2006 Jan 13. J Pharmacol Exp Ther. 2006. PMID: 16415090
-
Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(-)-RWAY.Synapse. 2007 Feb;61(2):96-105. doi: 10.1002/syn.20348. Synapse. 2007. PMID: 17117422
-
Disposition of enantiomers of sultopride in a human, rats and rabbits.Biol Pharm Bull. 1993 Nov;16(11):1121-3. doi: 10.1248/bpb.16.1121. Biol Pharm Bull. 1993. PMID: 7906175
-
In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.Drug Metab Dispos. 2008 Mar;36(3):481-4. doi: 10.1124/dmd.107.018176. Epub 2007 Dec 5. Drug Metab Dispos. 2008. PMID: 18057117
Cited by
-
Active Transport of Hepatotoxic Pyrrolizidine Alkaloids in HepaRG Cells.Int J Mol Sci. 2021 Apr 7;22(8):3821. doi: 10.3390/ijms22083821. Int J Mol Sci. 2021. PMID: 33917053 Free PMC article.
-
Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.Eur J Pharmacol. 2008 Jan 14;578(2-3):148-58. doi: 10.1016/j.ejphar.2007.09.035. Epub 2007 Oct 5. Eur J Pharmacol. 2008. PMID: 17963743 Free PMC article.
-
Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy.Biomed Res Int. 2015;2015:484963. doi: 10.1155/2015/484963. Epub 2015 Sep 27. Biomed Res Int. 2015. PMID: 26491671 Free PMC article. Review.
-
A RNA nanotechnology platform for a simultaneous two-in-one siRNA delivery and its application in synergistic RNAi therapy.Sci Rep. 2016 Aug 26;6:32363. doi: 10.1038/srep32363. Sci Rep. 2016. PMID: 27562435 Free PMC article.
-
Neuroleptic drugs revert the contextual fear conditioning deficit presented by spontaneously hypertensive rats: a potential animal model of emotional context processing in schizophrenia?Schizophr Bull. 2009 Jul;35(4):748-59. doi: 10.1093/schbul/sbn006. Epub 2008 Feb 16. Schizophr Bull. 2009. PMID: 18281713 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous